Ask AI
INAVO120
INAVO120: OS From Phase III Study of 1L Inavolisib/PBO + Palbociclib + Fulvestrant in PIK3CA-Mutated, HR+/HER2-, Endocrine-Resistant Advanced Breast Cancer 

Released: June 04, 2025

Expiration: December 03, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 04, 2025

Expiration: December 03, 2025